Under construction – not a live service

Skip to content

Frontlight Research

Institution

Zhongshan Hospital

Shanghai, ChinahealthcareWebsite

Also known as: Chung Shan Memorial Hospital · 中山医院 · 复旦大学附属中山医院

285running trials
80closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
NCT07866612· Source
Recruiting
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
NCT07775846· Phase 4· Source
Not yet recruiting
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
NCT07861425· Phase 1· Source
Not yet recruiting
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
NCT07919717· Phase 2· Source
Not yet recruiting
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
NCT07725484· Phase 3· Source
Not yet recruiting
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
NCT07691762· Phase 3· Source
Not yet recruiting
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
NCT07844187· Phase 1/2· Source
Recruiting
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
NCT07511166· Source
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672· Phase 3· Source
Not yet recruiting
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
NCT07823348· Phase 3· Source
Not yet recruiting
Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT07846267· Phase 2· Source
Not yet recruiting
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
NCT07812467· Phase 2· Source
Not yet recruiting
JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D
NCT07845955· Phase 2· Source
Recruiting
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
NCT07708441· Phase 2/3· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT07792954· Phase 3· Source
Recruiting
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979· Phase 3· Source
Not yet recruiting
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
NCT07829874· Phase 2· Source
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Source
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193· Phase 2· Source
Recruiting
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
NCT07653477· Phase 3· Source
Recruiting
Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
NCT07734857· Source
Not yet recruiting
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity
NCT07826364· Phase 1· Source
Not yet recruiting
A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.
NCT07794111· Phase 1· Source
Not yet recruiting
Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC
NCT07833241· Phase 2· Source
Not yet recruiting
Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer
NCT07810114· Phase 2· Source
Not yet recruiting
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
NCT07770672· Phase 2· Source
Not yet recruiting
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
NCT07693777· Phase 3· Source
Not yet recruiting
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
NCT07730489· Phase 3· Source
Not yet recruiting
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
NCT07765524· Phase 1/2· Source
Recruiting
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
NCT07856017· Source
Recruiting
QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
NCT07733115· Phase 2· Source
Not yet recruiting
Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction
NCT07621380· Phase 4· Source
Not yet recruiting
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
NCT07674615· Phase 1· Source
Not yet recruiting
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07682272· Phase 2· Source
Not yet recruiting
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
NCT07667517· Phase 4· Source
Not yet recruiting
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer
NCT07683403· Phase 1/2· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Source
Recruiting
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
NCT07623798· Phase 3· Source
Recruiting
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042· Source
Recruiting
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
NCT07768891· Phase 3· Source
Not yet recruiting
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
NCT07508956· Phase 3· Source
Recruiting
Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS
NCT07616037· Phase 2· Source
Not yet recruiting
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757· Phase 3· Source
Not yet recruiting
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
NCT07535632· Phase 2· Source
Not yet recruiting
Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction
NCT07616024· Source
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· Phase 1· Source
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
NCT07638683· Phase 2· Source
Recruiting
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
NCT07632677· Source
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892· Phase 2/3· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Liver and biliary tract cancer61 recruiting
Gastric and esophageal cancer27 recruiting
Colorectal cancer23 recruiting
Coronary artery disease15 recruiting
Lung cancer15 recruiting
Pancreatic cancer14 recruiting
Heart failure9 recruiting
Multiple myeloma9 recruiting
Obesity9 recruiting
Ovarian cancer8 recruiting
Type 2 diabetes8 recruiting
High blood pressure6 recruiting
Chronic kidney disease5 recruiting
Fatty liver disease (MASLD/MASH)5 recruiting
Childhood cancers4 recruiting
Head and neck cancer4 recruiting
Prostate cancer4 recruiting
Hypertrophic cardiomyopathy3 recruiting
Sarcoma3 recruiting
Amyloidosis2 recruiting
ANCA-associated vasculitis2 recruiting
Atrial fibrillation2 recruiting
Bladder cancer2 recruiting
IgA nephropathy2 recruiting
Stroke2 recruiting
Triple-negative breast cancer2 recruiting
Type 1 diabetes2 recruiting
Asthma1 recruiting
Cervical cancer1 recruiting
Diabetic eye disease1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Endometrial cancer1 recruiting
Follicular lymphoma1 recruiting
Hodgkin lymphoma1 recruiting
Kidney cancer1 recruiting
Metastatic breast cancer1 recruiting
Myasthenia gravis1 recruiting
Pulmonary arterial hypertension1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Completed
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
NCT07060885· Phase 3· Source
Completed
A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
NCT07035665· Phase 1· Source
Completed
Initial CT Perfusion-Guided Strategy for Suspected NSTEMI
NCT06689267· Source
Completed
Efficacy of Mazdutide for Treating PCOS
NCT06519656· Phase 1/2· Source
Completed
Augmented Reality Assisted Lung Nodule Localization: a Multicentered, Prospective, Randomly Controlled, Non-inferiority Trial
NCT06548451· Source
Completed
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
NCT06503250· Source
Completed
Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects
NCT06490991· Phase 1· Source
Terminated
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
NCT06462144· Early phase 1· Source
Completed
Evaluation of Electrical and Hemodynamic Effects of Different Pacing Strategies in CRT Candidates
NCT07032064· Source
Withdrawn
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
NCT06361758· Phase 2· Source
Completed
Efficacy of Dihydroartemisinin for Treating PCOS
NCT06417099· Phase 2· Source
Completed
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
NCT07319767· Source
Completed
Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards
NCT06319300· Source
Completed
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
NCT05940064· Phase 2· Source
Terminated
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
NCT06206278· Phase 2· Source
Completed
Robotic Natural Orifice Specimen Extraction Surgery Versus Robotic Transabdominal Specimen Extraction Surgery for Early-Stage Rectal Cancer
NCT06405308· Source
Completed
InsightPFA Trial of the LotosPFA Catheter
NCT06014996· Source
Completed
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
NCT06310590· Phase 1· Source
Completed
A Prospective, Multicenter, Blinded, Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of IVUS Console and IVUS Catheter in Coronary Intervention Procedures
NCT06974760· Source
Completed
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346· Phase 3· Source
Completed
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT05938920· Phase 2· Source
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897· Phase 3· Source
Completed
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
NCT05881837· Phase 2· Source
Completed
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
NCT07321613· Source
Completed
Scoreflex TRIO - Scoring PTCA Catheter
NCT05929313· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Source
Completed
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
NCT05702073· Phase 3· Source
Terminated
Multimodal Al for Precision Diagnosis of Esophageal Cancer
NCT07629921· Source
Completed
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
NCT05680129· Phase 3· Source
Completed
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231· Phase 2/3· Source
Completed
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT05367687· Phase 2· Source
Terminated
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
NCT05496569· Phase 2· Source
Completed
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
NCT05383482· Phase 1/2· Source
Completed
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
NCT05412004· Phase 3· Source
Completed
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
NCT05834868· Phase 3· Source
Completed
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801· Phase 3· Source
Completed
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
NCT05197842· Phase 1/2· Source
Terminated
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
NCT05149807· Phase 2/3· Source
Completed
Canagliflozin and Myocardial Fibrosis
NCT05367063· Phase 4· Source
Completed
Prehabilitation During Neoadjuvant Chemoradiotherapy for Rectal Cancer
NCT06542354· Source
Completed
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
NCT05262959· Phase 2· Source
Completed
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
NCT05093933· Phase 3· Source
Completed
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
NCT05047263· Phase 3· Source
Completed
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
NCT05008783· Phase 3· Source
Completed
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
NCT05004350· Phase 2· Source
Completed
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
NCT05054751· Phase 3· Source
Withdrawn
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
NCT05019677· Phase 2· Source
Completed
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04939142· Phase 3· Source
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818· Phase 1· Source
Completed
24 Hours Treatment with Alteplase in Patients with Ischemic Stroke
NCT04879615· Phase 3· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Liver and biliary tract cancer311 works · 87 trials
Lung cancer137 works · 31 trials
Gastric and esophageal cancer124 works · 45 trials
Heart failure102 works · 15 trials
Colorectal cancer89 works · 34 trials
Pancreatic cancer48 works · 18 trials
COPD43 works · 0 trials
Coronary artery disease40 works · 22 trials
Fatty liver disease (MASLD/MASH)29 works · 6 trials
Kidney cancer21 works · 3 trials
Hepatitis B20 works · 0 trials
Hypertrophic cardiomyopathy18 works · 5 trials
Neuroendocrine tumours18 works · 2 trials
Thyroid cancer10 works · 1 trials
IgA nephropathy9 works · 4 trials
High blood pressure5 works · 9 trials

Institution data: ROR 032x22645 (CC0-1.0)Updated 10 Nov 2026

Report an error